Xiandeng Li , Shuyan Zhao , Mi Li , Xiaodong Xing , Jing Xie , Mo Wang , Ajing Xu , Qinjian Zhao , Jian Zhang
{"title":"Wogonoside ameliorates oxidative damage in tubular epithelial cells of diabetic nephropathy by modulating the HNF4A-NRF2 axis","authors":"Xiandeng Li , Shuyan Zhao , Mi Li , Xiaodong Xing , Jing Xie , Mo Wang , Ajing Xu , Qinjian Zhao , Jian Zhang","doi":"10.1016/j.intimp.2025.114481","DOIUrl":null,"url":null,"abstract":"<div><div>Diabetic nephropathy (DN), a leading cause of end-stage renal disease, presents significant challenges due to its complex pathophysiology and limited effective treatment options. Increasing evidence suggests that tubular injury is an early event preceding glomerular damage in DN. Wogonoside, a natural flavonoid derived from <em>Scutellaria baicalensis</em>, has not been previously reported for DN treatment. This study aims to investigate the protective effects and underlying mechanisms of wogonoside on renal tubular epithelial cells (TECs) in DN. The results showed that wogonoside mitigates high glucose (HG)-induced oxidative stress in TCMK-1 cells. Additionally, wogonoside protects renal function, reduces renal tubular damage, and modulates the oxidative stress response in HFD/STZ-induced DN mouse model. Importantly, our results indicated that hepatocyte nuclear factor 4 alpha (HNF4A) expression is downregulated in the kidneys of DN mice and HG-induced TCMK-1 cells. Wogonoside can bind to HNF4A, upregulate its expression, and promote nuclear translocation. Bioinformatic analysis suggested that NRF2 might be a downstream signaling of HNF4A. This was confirmed by Co-IP and experiments involving HNF4A overexpression and NRF2 knockdown, which demonstrated that wogonoside regulates the HNF4A-NRF2 axis to alleviate oxidative stress in TECs. Collectively, these findings identify wogonoside as a possible therapeutic agent for DN, highlighting HNF4A as a promising target for intervention.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"152 ","pages":"Article 114481"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925004710","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic nephropathy (DN), a leading cause of end-stage renal disease, presents significant challenges due to its complex pathophysiology and limited effective treatment options. Increasing evidence suggests that tubular injury is an early event preceding glomerular damage in DN. Wogonoside, a natural flavonoid derived from Scutellaria baicalensis, has not been previously reported for DN treatment. This study aims to investigate the protective effects and underlying mechanisms of wogonoside on renal tubular epithelial cells (TECs) in DN. The results showed that wogonoside mitigates high glucose (HG)-induced oxidative stress in TCMK-1 cells. Additionally, wogonoside protects renal function, reduces renal tubular damage, and modulates the oxidative stress response in HFD/STZ-induced DN mouse model. Importantly, our results indicated that hepatocyte nuclear factor 4 alpha (HNF4A) expression is downregulated in the kidneys of DN mice and HG-induced TCMK-1 cells. Wogonoside can bind to HNF4A, upregulate its expression, and promote nuclear translocation. Bioinformatic analysis suggested that NRF2 might be a downstream signaling of HNF4A. This was confirmed by Co-IP and experiments involving HNF4A overexpression and NRF2 knockdown, which demonstrated that wogonoside regulates the HNF4A-NRF2 axis to alleviate oxidative stress in TECs. Collectively, these findings identify wogonoside as a possible therapeutic agent for DN, highlighting HNF4A as a promising target for intervention.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.